TW
IMMX icon

TritonPoint Wealth’s Immix Biopharma IMMX Stock Holding History

TritonPoint Wealth’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-24,526
Closed -$51.3K – 311
2025
Q3 		$51.3K Hold
24,526
– – ﹤0.01% 348
2025
Q2 		$50.8K Buy
+24,526
New +$49.4K ﹤0.01% 342
2024
Q4 		– Sell
-24,526
Closed -$38.3K – 341
2024
Q3 		$38.3K Hold
24,526
– – ﹤0.01% 329
2024
Q2 		$48.6K Hold
24,526
– – ﹤0.01% 317
2024
Q1 		$170K Buy
+24,526
New +$95K 0.02% 304

Other funds holding IMMX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

TritonPoint Wealth's IMMX Position: Q4 2025 in Review

TritonPoint Wealth sold out of Immix Biopharma (IMMX) in Q4 2025, closing a stake of 24,526 shares — an estimated $51.3K sold.

TritonPoint Wealth first reported a position in IMMX in Q1 2024 and held it in 5 quarters. The position peaked at $170K in Q1 2024. 67 funds tracked by Wall St. Rank hold IMMX as of Q4 2025.

  • TritonPoint Wealth reported no remaining Immix Biopharma position as of Q4 2025 after selling out during the quarter.
  • TritonPoint Wealth sold 24,526 Immix Biopharma shares in Q4 2025, an estimated $51.3K.
  • TritonPoint Wealth first reported a position in Immix Biopharma in Q1 2024 and held it in 5 quarters.
  • TritonPoint Wealth's Immix Biopharma position peaked at $170K in Q1 2024.
  • 67 funds tracked by Wall St. Rank held Immix Biopharma as of Q4 2025.

Based on TritonPoint Wealth's 13F filing for Q4 2025, filed 20 Jan 2026.